![]() |
市場調查報告書
商品編碼
1847177
美國輸液治療設備市場:市場規模、佔有率和趨勢分析(2026-2032 年)Infusion Therapy Market Size, Share & Trends Analysis | United States | 2026-2032 | Includes: Irrigation Solutions, Drug Reconstitution, and 3 more |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到2025年,美國輸液治療設備市場規模將超過41億美元。預計到2031年,該市場將以2.3%的複合年成長率成長,超過48億美元。
本報告涵蓋輸液幫浦、輸液器、無針接頭、三通閥、靜脈過濾器和輸血裝置。報告量化了產品數量、平均售價、市場價值、成長率和企業市場占有率。此外,報告還分析了成長促進因素、近期併購活動、召回事件和技術趨勢。報告提供截至2024年的歷史數據,並預測至2031年。
它反映了醫療系統如何評估醫院、專科診所、門診手術中心、家庭輸液聯網智慧幫浦、藥物庫、減少管理錯誤軟體和 EMR互通性。
市場概覽
醫院和醫療網路正在從傳統的資本更新周期轉向完全連網的輸液平台。
這些平台結合了藥物庫、管理錯誤減少軟體和即時 EMR通訊,實現了自動化程式設計和文件記錄。
這種轉變增加了前期成本,並增加了軟體授權、分析、網路安全、介面檢驗、培訓和藥物庫管治等方面的持續支出。由於安全更新和新功能依賴於支援的硬體和軟體基準,因此系統更新的頻率也比以往更高。
因此,即使銷售量成長不大,由於平均售價、訂閱費和付費服務的成長,市場價值也將上升。從長遠來看,企業採購決策正在轉變,優先考慮標準化泵浦組、系統整合和資料服務,而不是一次性設備採購。
市場促進因素
智慧型輸液幫浦和互通性。減少給藥誤差、標準化藥物庫以及雙向電子病歷整合,可提高安全性和工作流程效率。這些功能需要檢驗的介面和管治,從而提高平均售價和服務收入。
感染預防 - 醫院承擔導管相關血流感染的成本,這促使醫院採用用於感染預防的高級設備和耗材,包括分離隔膜連接器、中性位移設計和抗菌選項。
其他照護場所-家庭輸液和其他非急性照護在醫療服務中所佔比例越來越高。這些場所的採購較為分散,通常無法從集團採購組織 (GPO) 獲得折扣,因此價格較高。
生命週期和網路安全 - 定期的安全性修補程式、召回和功能發布加快了更換週期,並保持產品平臺活躍。
臨床生產力——一個簡化藥物庫管理、警報緩解、車隊監控和分析的平台,幫助大型醫療保健系統安全精益地營運,從而增強了網路升級的必要性。
市場限制
不利事件和召回 - 安全問題,包括泵召回,擾亂營運,給庫存帶來壓力,並提高新安裝的實質審查閾值。
非器材競爭-新藥和非侵入性治療方法可能在某些適應症中取代器材的使用。例如,長效局部止痛藥在周邊神經阻斷途徑的應用降低了對某些拋棄式門診鎮痛幫浦的需求。
集團採購組織 (GPO) 集中需求並協商更低的價格,這可能會限制小型製造商進入市場,並減緩新設備的採用。
證據缺口-由於缺乏結果證據,某些高級功能(例如某些連接器上的抗菌塗層)的成長速度將會放緩。
價格壓力-成熟的競爭格局和合約週期意味著,即使軟體和服務不斷擴張,某些類別的價格上漲幅度也較為溫和。
目標市場和數據範圍
定量範圍
市場規模、市佔率、市場預測、成長率、銷售量、平均售價
定性範圍
成長趨勢、阻礙因素、競爭對手競爭分析及SWOT分析、併購、公司簡介及產品系列、FDA召回、顛覆性技術、疾病概述,這些因素共同影響輸液治療的需求。
時期
基準年:2025年,預測期間:2026-2032年,歷史資料:2022-2024年
數據來源
對產業領導者的初步訪談、政府醫師資料、監管資料、私人醫院資料、進出口資料、iData Research 內部資料庫。
方法
收入模型為單位銷售量乘以平均售價,透過程序和使用率輸入檢驗,並與泵浦和設備的安裝基礎和更換假設進行核對。
治療地點
醫院、專科診所、門診手術中心及居家醫療
目標市場及區隔
輸液幫浦市場
單元分析適用於大容量幫浦和注射式幫浦。
輸液器市場(IV 套裝)
水泵組
重力組和輔助組
依材質分類的擴展套裝。 DEHP 套裝和非 DEHP 套裝。
無針連接器市場
止水閥市場
靜脈輸液過濾器市場
輸血器市場
輸血加溫器市場
競爭分析
2025 年,貝克頓·迪金森公司在美國輸液治療設備和耗材市場佔領先地位。收購 CareFusion 後,該公司擴大了在輸液設備領域的地位,並在輸液器和無針連接器領域獲得了領先地位。
ICU Medical是第二大競爭對手,在輸液幫浦、輸液器和無針接頭領域擁有強大的市場佔有率,並在三通閥領域佔領先地位。 2022年收購Smiths Medical後,該公司已做好充分準備,進一步拓展產品線。
百特在輸液幫浦、輸液器、無針接頭、三通閥和輸血器領域擁有廣泛的市場佔有率,位居第三。雖然該公司並非區隔市場的領導者,但憑藉其龐大的分銷網路,百特的產品能夠觸及眾多醫療服務提供者。
其他參與企業則活躍於特定產品或醫療領域。
這是一個高度集中的市場,有利於對品質、軟體和服務進行持續投資,同時也提高了新進入者的門檻。
科技與臨床趨勢
藥物庫和劑量誤差減少是大規模部署的標準要求。
中性或最小反流連接器價格較高,因為人們認為它們發生血液逆流和阻塞的風險較低。
抗菌或可消毒設計在證據和工作流程支持其價值的情況下正獲得越來越多的支持。
警報和分析用於減少誤報、發現培訓差距和規劃維護。
家庭輸液物流和報銷持續擴大,市場在急性和非急性環境中仍保持多元化。
地區
本報告涵蓋美國。
美國輸液治療設備市場中規模最大、成長最快的區隔市場是什麼?在預測期內,哪些類別可能獲得最大的市佔率?
輸液治療設備市場與更廣泛的經濟和醫院管理有何關係?包括整合、網路安全支出以及向標準化和企業平台的轉變?
未來哪些因素將影響市場格局,包括電子病歷互通性、減少管理錯誤、感染預防、召回、證據要求、集團採購組織合約以及替代醫療場所的興起?
智慧型幫浦、藥物庫和自動編程將如何改變更換週期?這將對定價、訂閱和付費服務產生什麼影響?
根據感染風險、消毒效果和易用性,連接器、組件和旋塞等產品設計中哪些正在獲得市場認可?
召回和不利事件報告如何影響醫療機構的採購決策和供應商選擇。
供應商如何透過將安全功能、警報管理和分析與臨床生產力和成本控制聯繫起來,來加強其商業案例。
商業團隊應該如何規劃家庭輸液的成長、分散的採購以及 GPO 合約以外的定價策略?
成長面臨的主要風險是什麼?例如,非器械療法是否會減少某些治療途徑中器械的使用?
iData Research 的「美國輸液治療設備市場報告」透過流程感知模型、企業市場占有率分析和定價詳情來回答這些問題。
這份報告可用於依類別量化需求、規劃產品藍圖、設定定價和合約目標,以及優先考慮能夠加速產品普及的培訓和支援計畫。
目錄
圖表清單
圖表列表
美國輸液治療設備市場概覽
競爭分析
新興市場與技術
市場趨勢
市場趨勢
市場區隔
重要報告更新
版本歷史記錄
調查方法
全球關稅的影響
美國輸液治療設備市場概覽
輸液幫浦市場
輸液器市場
無針連接器市場
止水閥市場
靜脈輸液過濾器市場
輸血設備市場
輸血加溫器市場
The U.S. infusion therapy device market was valued at over $4.1 billion in 2025. The market is expected to grow at a 2.3 percent CAGR to exceed $4.8 billion by 2031.
This report covers infusion pumps, infusion sets, needleless connectors, stopcocks, intravenous filters, and devices used for blood transfusion. It quantifies units, average selling prices, market values, growth rates, and company shares, and it analyzes growth drivers and limiters, recent M&A, recalls, and technology trends. It provides historical data to 2024 and forecasts to 2031.
The scope reflects how health systems evaluate networked smart pumps, drug libraries, dose-error reduction software, and EMR interoperability across hospitals, specialty clinics, ambulatory surgical centers, and home infusion.
Market Overview
Hospitals and health networks are moving from legacy capital replacement cycles toward fully networked infusion platforms.
These platforms combine drug libraries, dose-error reduction software, and real-time EMR communication for auto programming and auto documentation.
This shift increases upfront costs and adds ongoing fees for software licensing, analytics, cybersecurity, interface validation, training, and drug-library governance. Because security updates and new features depend on supported hardware and software baselines, fleets are refreshed more often than in the past.
As a result, market value rises through higher ASPs, subscriptions, and paid services, even when unit growth is modest. Over time, purchasing is becoming an enterprise decision that favors standardized pump fleets, system integration, and data services rather than one-off device buys.
Market Drivers
Smart pumps and interoperability. Dose-error reduction, standardized drug libraries, and bidirectional EMR integration improve safety and workflow. These features require validated interfaces and governance, which supports higher ASPs and service revenues.
Infection prevention. Hospitals carry the cost of catheter-related bloodstream infections. This drives adoption of premium infection-prevention devices and consumables, including split septum connectors, neutral displacement designs, and antimicrobial options where evidence supports use.
Alternate care sites. Home infusion and other non-acute settings are a rising share of therapy. Purchasing in these settings is fragmented and often has fewer GPO discounts, which supports higher price realization.
Lifecycle and cybersecurity. Regular security patches, recalls, and feature releases accelerate replacement cycles and keep product pipelines active.
Clinical productivity. Platforms that simplify drug-library management, alarm reduction, fleet monitoring, and analytics help large health systems run safer and leaner, which strengthens the case for networked upgrades.
Market Limiters
Adverse events and recalls. Safety issues, including pump recalls, disrupt operations and strain inventory. They also raise due diligence thresholds for new placements.
Non-device competition. New drugs and non-invasive therapies can displace device usage in select indications. An example is long-acting local analgesia in peripheral nerve block pathways, which reduced demand for some disposable ambulatory pain pumps.
Group purchasing organizations. GPOs aggregate demand and negotiate lower prices, which can limit market access for smaller manufacturers and can slow adoption of novel devices.
Evidence gaps. Some premium features, such as antimicrobial coatings on certain connectors, face slower growth where outcome evidence is limited.
Pricing pressure. A mature competitive field and contract cycles keep price gains moderate in several categories, even as software and services expand.
Market Coverage and Data Scope
Quantitative coverage
Market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
Qualitative coverage
Growth trends, limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, FDA recalls, disruptive technologies, and disease overviews that shape demand for infusion therapy.
Time frame
Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.
Data sources
Primary interviews with industry leaders, government physician data, regulatory data, hospital private data, import and export data, and the iData Research internal database.
Method note
Revenue is modeled from units multiplied by ASP, validated with procedure and utilization inputs, and checked against installed base and replacement assumptions for pumps and sets.
Care settings
Hospitals, specialty clinics, ambulatory surgical centers, and home care.
Markets Covered and Segmentation
Infusion Pump Market
Unit analysis applies to large volume and syringe pumps.
Intravenous Set Market (IV sets)
Pump sets.
Gravity sets and secondary sets.
Extension sets by material. DEHP sets and non-DEHP sets.
Needleless Connector Market
Stopcock Market
Intravenous Filter Market
Blood Transfusion Set Market
Blood Warmer Market
Competitive Analysis
Becton Dickinson led the U.S. infusion therapy device and consumables market in 2025. The company expanded its position in IV devices after acquiring CareFusion and holds leadership in IV sets and needleless connectors.
ICU Medical was the second-largest competitor with strong shares in infusion pumps, IV sets, and needleless connectors, and leadership in stopcocks. After acquiring Smiths Medical in 2022, the company is positioned for further product activity.
Baxter ranked third in total share with a broad presence in infusion pumps, IV sets, needleless connectors, stopcocks, and blood transfusion sets. The company is not the segment leader but maintains wide access across provider types through an extensive distribution network.
Other participants are active in selected products or care settings.
This is a concentrated market that supports sustained investment in quality, software, and services and that also raises the bar for new entrants.
Technology and Practice Trends
Drug libraries and dose-error reduction are standard requirements in large placements.
Neutral or minimal reflux connectors command a premium due to lower perceived risk of blood reflux and occlusion.
Antimicrobial or disinfectable designs gain traction where evidence and workflow support the value case.
Alarm and analytics features are used to reduce nuisance alarms, find training gaps, and plan maintenance.
Home infusion logistics and reimbursement continue to expand, which keeps the market diverse across acute and non-acute buyers.
Geography
This edition covers the United States.
Where is the largest and fastest growing opportunity within U.S. infusion therapy devices and which categories are most likely to gain share over the forecast period.
How does the infusion therapy device market relate to the broader economy and to hospital operations, including consolidation, cybersecurity spending, and the shift toward standardization and enterprise platforms.
What forces will shape the market going forward, including EMR interoperability, dose-error reduction, infection prevention, recalls, evidence requirements, GPO contracts, and the rise of alternate care sites.
How do smart pumps, drug libraries, and auto programming change replacement cycles and what are the implications for pricing, subscriptions, and paid services.
Which product designs are gaining traction in connectors, sets, and stopcocks based on infection risk, disinfection profiles, and ease of use.
What is the impact of recalls and adverse event reporting on provider purchasing decisions and vendor selection.
How can suppliers make a stronger business case by linking safety features, alarm management, and analytics to clinical productivity and cost control.
How should commercial teams plan for home infusion growth, fragmented purchasing, and pricing strategies outside GPO contracts.
Where are the key risks to growth, including non-device therapies that reduce device usage in specific pathways.
The U.S. infusion therapy device market report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail.
Use it to quantify demand by category, plan product roadmaps, set pricing and contracting targets, and prioritize training and support programs that speed adoption.
Table Of Contents
List Of Figures
List Of Charts
U.S. Infusion Therapy Device Market Overview
Competitive Analysis
Emerging Markets And Technologies
Market Trends
Market Developments
Market Segmentation
Key Report Updates
Version History
Research Methodology
Impact Of Global Tariffs
U.S. Infusion Therapy Device Market Overview
Infusion Pump Market
Intravenous Set Market
Needleless Connector Market
Stopcock Market
Intravenous Filter Market
Blood Transfusion Device Market
Blood Warmer Market
Figure 9-8 Other Blood Transfusion Device Market, U.S., 2022 - 2032